We classified NF1 mutations as a MAPK alteration, consistent with recent breast cancer literature, and because of the greater interest in targeting NF1 germline-mutant tumors with MAPK targeting NF1. 27,28 MAPK pathway is involved in many cellular processes including cell proliferation, differentiation, and transcriptional regulation. This evidence concerns the gene NF1 and breast carcinoma.